Below are the most recent publications written about "Antihypertensive Agents" by people in Profiles.
-
Wong MK, Bowers ME, Ventimiglia J, Niknam RM, Moster MR, Pro MJ, Dale E, Kolomeyer NN, Lee D, Zheng CX. Short-Term Outcomes of Bimatoprost Sustained-Release Intracameral Implant in Glaucoma. J Glaucoma. 2023 09 01; 32(9):738-743.
-
Ahmed M, Nudy M, Bussa R, Naccarelli GV, Filippone EJ, Foy AJ. A Subgroup Meta-Analysis Comparing the Renal Denervation Sham-Controlled Randomized Trials Among Those With Resistant and Nonresistant Hypertension. Am J Cardiol. 2023 Mar 15; 191:119-124.
-
Groenland EH, Dasgupta I, Visseren FLJ, van der Elst KCM, Lorde N, Lawson AJ, Bots ML, Spiering W. Clinical characteristics do not reliably identify non-adherence in patients with uncontrolled hypertension. Blood Press. 2022 12; 31(1):178-186.
-
Szabo Yamashita T, Shariq OA, Foster TR, Lyden ML, Dy BM, Young WF, Bancos I, McKenzie TJ. Unilateral Adrenalectomy for Primary Aldosteronism Due to Bilateral Adrenal Disease Can Result in Resolution of Hypokalemia and Amelioration of Hypertension. World J Surg. 2023 Feb; 47(2):314-318.
-
Sahai SK, Balonov K, Bentov N, Bierle DMM, Browning LM, Cummings KC, Dougan BM, Maxwell M, Merli GJ, Oprea AD, Sweitzer B, Mauck KF, Urman RD. Preoperative Management of Cardiovascular Medications: A Society for Perioperative Assessment and Quality Improvement (SPAQI) Consensus Statement. Mayo Clin Proc. 2022 09; 97(9):1734-1751.
-
Wong JC, Shiuey EJ, Razeghinejad R, Shukla AG, Kolomeyer NN, Myers JS, Pro MJ, Lee D. The effectiveness and tolerability of fixed-dose combination netarsudil 0.02%/latanoprost 0.005% at a tertiary glaucoma center. Graefes Arch Clin Exp Ophthalmol. 2023 Jan; 261(1):193-200.
-
Filippone EJ, Foy AJ, Naccarelli GV. Controversies in Hypertension II: The Optimal Target Blood Pressure. Am J Med. 2022 10; 135(10):1168-1177.e3.
-
Bello NR, LaMattina KC, Minor JM, Utz VM, Dong K, Levin AV. The risk of uveitis due to prostaglandin analogs in pediatric glaucoma. J AAPOS. 2022 06; 26(3):126.e1-126.e5.
-
Dasgupta I, Zoccali C. Is the KDIGO Systolic Blood Pressure Target <120 mm?Hg for Chronic Kidney Disease Appropriate in Routine Clinical Practice? Hypertension. 2022 01; 79(1):4-11.
-
Lane D, Lawson A, Burns A, Azizi M, Burnier M, Jones DJL, Kably B, Khunti K, Kreutz R, Patel P, Persu A, Spiering W, Toennes SW, Tomaszewski M, Williams B, Gupta P, Dasgupta I. Nonadherence in Hypertension: How to Develop and Implement Chemical Adherence Testing. Hypertension. 2022 01; 79(1):12-23.